Oculis Holding AG announced the completion of the final patient visit in its Phase 3 DIAMOND program testing OCS-01 eye drops for diabetic macular edema (DME), involving over 800 patients. This non-invasive topical treatment aims to provide an alternative to current invasive therapies, addressing unmet needs for early intervention and patients poorly responding to existing treatments. Topline results are expected in June 2026, with a potential regulatory submission planned for Q4 2026. If successful, OCS-01 could transform DME treatment by offering an easier, less burdensome option for a condition affecting millions worldwide.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
